Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888448 | 0.87 | HPGD (0.42) | SMN1; SMN2HPGDTLR7TSHRPDE10A | |
| SCHEMBL4160877 | 0.83 | TLR7 (0.46) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL4152038 | 0.82 | TLR7 (0.46) | TLR7TLR8 | |
| SCHEMBL7089565 | 0.80 | TLR7 (0.47) | KMT2AMEN1TLR7PDE10ATLR8 | |
| SCHEMBL4147523 | 0.79 | GAA (0.43) | GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4790754 | 0.78 | TLR7 (0.53) | TLR7TLR8 | |
| SCHEMBL4309229 | 0.77 | STING1 (0.46) | GAAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL1140896 | 0.77 | TLR7 (0.36) | GAAKMT2AMEN1SMN1; SMN2TLR7 | |
| SCHEMBL24414984 | 0.76 | TLR7 (0.51) | SMN1; SMN2TLR7TSHRPDE10ATLR8 | |
| SCHEMBL4160522 | 0.76 | TLR7 (0.56) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8343993-B2 | Hydroxyalkyl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC, (US) | 2009-10-08 | — | — | US | disclosed |
| US-7557162-B2 | Toughened polymer compositions | TEKNOR APEX COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080182965-A1 | Materials Free of Endocrine Disruptive Activity | PLASTIPURE, INC. | 2008-07-31 | — | — | US | disclosed |
| EP-1851220-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091568-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-7041741-B2 | Toughened polymer compositions | TEKNOR APEX COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050154135-A1 | Toughened polymer compositions | TEKNOR APEX COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-20050154134-A1 | Toughened polymer compositions | TEKNOR APEX COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | GAA 774/4885KMT2A 2737/4885MEN1 4113/4885 |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | IFNG, IFNAR1, IRF3 | GAA 607/4885KMT2A 2533/4885MEN1 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.